首页 | 本学科首页   官方微博 | 高级检索  
检索        

血清补体C1q、RBP及尿mALB联合检测在儿童过敏性紫癜早期肾损伤中的临床意义
引用本文:乐高钟,吴小秧,吴志坚,廖永强,罗勤.血清补体C1q、RBP及尿mALB联合检测在儿童过敏性紫癜早期肾损伤中的临床意义[J].检验医学与临床,2021,18(3):318-321.
作者姓名:乐高钟  吴小秧  吴志坚  廖永强  罗勤
作者单位:江西省萍乡市人民医院:儿科,江西萍乡 337000;江西省萍乡市人民医院:儿科,江西萍乡 337000;江西省萍乡市人民医院:儿科,江西萍乡 337000;江西省萍乡市人民医院:检验科,江西萍乡 337000;江西省萍乡市人民医院:儿科,江西萍乡 337000
基金项目:江西省卫生健康委员会科技计划资助项目
摘    要:目的探讨血清补体C1q、视黄醇结合蛋白(RBP)及尿微量清蛋白(mALB)联合检测在儿童过敏性紫癜(HSP)早期肾损伤中的临床意义。方法选取该院2017年7月至2018年12月住院的70例HSP患儿作为观察组,其中单纯型HSP 50例,合并紫癜性肾炎(HSPN)20例;另选取同期该院健康体检儿童30例作为对照组。对所有受试儿童血清补体C1q、RBP及尿mALB水平进行比较分析;同时对观察组治疗前后血清补体C1q、RBP及尿mALB水平进行比较分析;并对HSPN患儿血清补体C1q、RBP及尿mALB单项检测阳性率及联合检测阳性率进行比较。结果与对照组比较,HSP组及HSPN组血清补体C1q水平均升高,HSPN组与对照组差异有统计学意义(P<0.05),但HSP组与对照组差异无统计学意义(P>0.05);与对照组及HSP组比较,HSPN组血清RBP及尿mALB水平差异均有统计学意义(P<0.05);与对照组比较,HSP组尿mALB水平差异有统计学意义(P<0.05),但血清RBP水平差异无统计学意义(P>0.05)。HSPN患儿血清补体C1q、RBP及尿mALB三者联合检测阳性率明显高于单项检测,差异均有统计学意义(P<0.05)。观察组治疗后血清补体C1q、RBP及尿mALB水平与治疗前比较均下降,但三者水平仍高于对照组,差异均有统计学意义(P<0.05)。结论血清补体C1q、RBP及尿mALB联合检测在儿童HSP早期预示肾损伤中有重要临床指导意义。

关 键 词:肾损伤  补体C1Q  视黄醇结合蛋白  尿微量清蛋白  过敏性紫癜  儿童

The clinical value on the serum level of Complement C1q,RBP and urinary mALB in children of early renal injury with Henoch-Schonlein Purpura
LE Gaozhong,WU Xiaoyang,WU Zhijian,LIAO Yongqiang,LUO Qin.The clinical value on the serum level of Complement C1q,RBP and urinary mALB in children of early renal injury with Henoch-Schonlein Purpura[J].Laboratory Medicine and Clinic,2021,18(3):318-321.
Authors:LE Gaozhong  WU Xiaoyang  WU Zhijian  LIAO Yongqiang  LUO Qin
Institution:(Department of Pediatrics;Department of Clinical Laboratory,Pingxiang People′s Hospital,Pingxiang,Jiangxi 337000,China)
Abstract:Objective To investigate the clinical significance of serum level of Complement C1q,retinol binding protein(RBP)and urinary micro-albumin(mALB)in children of early renal injury with Henoch-Schonlein Purpura(HSP).Methods A total of 70 cases of children of HSP hospitalized in the hospital from July 2017 to December 2018 were selected as the observation group,including 50 cases of simple type of HSP,20 cases of Henoch-Schonlein Purpura Nephritis(HSPN).Thirty healthy children who underwent health examination in the hospital during the same period were selected as control group.The levels of serum Complement C1q,RBP and urinary mALB of the subjects in three groups were compared and analyzed.At the same time,the levels of serum Complement C1q,RBP and urinary mALB before and after treatment in the observation group were compared and analyzed.The positive rate of serum level of Complement C1q,RBP and urinary mALB individually and combined for the children of HSPN were compared and analyzed.Results Compared with control group,the levels of serum Complement C1q in HSP group and HSPN group were increased,the difference between HSPN group and control group was statistically significant(P<0.05),while the difference between HSP group and control group was not statistically significant(P>0.05).Compared with the control group and HSP group,there were significant differences on the levels of serum RBP and urinary mALB in HSPN group(P<0.05).Compared with the control group,there was significant difference on urinary mALB level in HSP group(P<0.05),but there was no significant difference on serum RBP level(P>0.05).The positive rate of combined detection of serum complement C1q,RBP and urine mALB in children with HSPN was significantly higher than that of single detection,and the difference was statistically significant(P>0.05).After treatment,the levels of serum complement C1q,RBP and urine mALB in the observation group decreased,but the three levels were still higher than those in the control group,and the differences were statistically significant(P>0.05).Conclusion The combined detection of complement C1q,RBP and urinary mALB has important guiding significance for the clinical to forecast renal injury in children with HSP.
Keywords:renal injury  complement C1q  retinol binding protein  urinary micro-albumin  henoch-schonlein Purpura  children
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号